US Patent No: 7,368,126

Number of patents in Portfolio can not be more than 2000

Controlled release depot formulations

ALSO PUBLISHED AS: 20040151753

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods and compositions for systemically or locally administering a beneficialagent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a prolonged duration of time. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
DURECT CORPORATIONCUPERTINO, CA82

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bannister, Roy Hollister, CA 3 36
Chen, Guohua Sunnyvale, CA 92 840
Houston, Paul Hayward, CA 8 56
Kameda, Teresa Sunnyvale, CA 2 6
Kleiner, Lothar Los Altos, CA 47 477
Priebe, David Seattle, WA 6 38

Cited Art Landscape

Patent Info (Count) # Cites Year
 
ALZA CORPORATION (12)
4,865,845 Release rate adjustment of osmotic or diffusional delivery devices 126 1987
5,112,614 Implantable delivery dispenser 118 1989
5,057,318 Delivery system for beneficial agent over a broad range of rates 139 1990
5,059,423 Delivery system comprising biocompatible beneficial agent formulation 122 1990
5,137,727 Delivery device providing beneficial agent stability 133 1991
5,209,746 Osmotically driven delivery devices with pulsatile effect 49 1992
5,234,692 Delivery device with a protective sleeve 112 1992
5,234,693 Delivery device with a protective sleeve 113 1992
5,308,348 Delivery devices with pulsatile effect 74 1993
5,456,679 Delivery devices with pulsatile effect 48 1994
5,620,700 Injectable drug delivery system and method 53 1995
2005/0281,879 Excipients in drug delivery vehicles 2 2004
 
DURECT CORPORATION (8)
5,151,093 Osmotically driven syringe with programmable agent delivery 29 1990
6,130,200 Gel composition and methods 77 1997
6,331,311 Injectable depot gel composition and method of preparing the composition 61 1997
2003/0180,364 Catheter injectable depot compositions and uses thereof 12 2002
2004/0024,069 Injectable depot compositions and uses thereof 14 2002
2004/0001,889 Short duration depot formulations 20 2003
2004/0022,859 Injectable multimodal polymer depot compositions and uses thereof 13 2003
2005/0106,214 Excipients in drug delivery vehicles 7 2004
 
ATRIX LABORATORIES, INC. (6)
4,938,763 Biodegradable in-situ forming implants and methods of producing the same 435 1988
5,278,201 Biodegradable in-situ forming implants and methods of producing the same 239 1990
5,599,552 Biodegradable polymer composition 93 1994
5,733,950 Biodegradable in-situ forming implants and methods of producing the same 76 1995
5,780,044 Liquid delivery compositions 91 1996
5,990,194 Biodegradable in-situ forming implants and methods of producing the same 82 1997
 
ETHICON, INC. (6)
5,468,253 Elastomeric medical device 210 1993
5,713,920 Elastomeric medical device 44 1995
5,639,851 High strength, melt processable, lactide-rich, poly(lactide-CO-P-dioxanone) copolymers 15 1995
5,714,551 High strength, melt processable, lactide-rich, poly (lactide-co-p-dioxanone) copolymers 53 1996
5,868,788 High-strength, melt-processable, lactade-rich, poly(lactade-co-p-dioxanone) copolymers 5 1997
6,113,624 Absorbable elastomeric polymer 24 1999
 
Alkermes Controlled Therapeutics, Inc. (2)
5,656,297 Modulated release from biocompatible polymers 146 1994
5,654,010 Composition for sustained release of human growth hormone 98 1995
 
BETZ LABORATORIES, INC. (1)
4,443,340 Control of iron induced fouling in water systems 38 1983
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
5,651,986 Controlled local delivery of chemotherapeutic agents for treating solid tumors 94 1996
 
MITSUI CHEMICALS, INC. (1)
5,310,865 Polyhydroxycarboxylic acid and preparation process thereof 52 1992
 
MONSANTO TECHNOLOGY LLC (1)
4,985,404 Prolonged release of biologically active polypeptides 26 1988
 
Nippon Densan Corporation (1)
5,336,057 Micropump with liquid-absorptive polymer gel actuator 28 1993
 
ONC SOLUTIONS, INC. (1)
8,320,995 Fiducial marker with rings 1 2007
 
REILLY INDUSTRIES, INC. (1)
5,556,905 Physically-modified degradable thermoplastic compositions 17 1994
 
SCHERING CORPORATION (1)
4,853,218 Zinc-protamine-alpha interferon complex 25 1987
 
SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (1)
5,279,608 Osmotic pumps 86 1991
 
SOUTHERN RESEARCH INSTITUTE (1)
5,085,866 Method of producing zero-order controlled-released devices 24 1988
 
The Procter & Gamble Company (1)
5,242,910 Sustained release compositions for treating periodontal disease 30 1992
 
TIMKEN COMPANY, THE (1)
2003/0170,289 Injectable depot compositions and uses thereof 10 2002
 
Other [Check patent profile for assignment information] (1)
6,432,438 Biodegradable vehicle and filler 33 2000

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
ALLERGAN, INC. (2)
8,425,929 Sustained release intraocular implants and methods for preventing retinal dysfunction 0 2004
8,580,292 Sustained release intraocular implants and methods for treating ocular vasculopathies 0 2008
 
PIRAMAL HEALTHCARE LIMITED (2)
8,389,467 In situ self-setting mineral-polymer hybrid materials, composition and use thereof 0 2009
8,258,117 Composition and method for the repair and regeneration of cartilage and other tissues 0 2010
 
PIRAMAL HEALTHCARE (CANADA) LTS. (1)
8,747,899 Injectable in situ self-forming mineral-polymer hybrid composition and uses thereof 0 2009
 
WARSAW ORTHOPEDIC, INC. (1)
8,591,935 Methods and compositions for treating pain comprising a statin 0 2011

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Nov 6, 2015
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 6, 2019
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00